Activity of faropenem against cephalosporin-resistant Enterobacteriaceae

Shazad Mushtaq; Russell Hope; Marina Warner; David M Livermore

doi:10.1093/jac/dkm063

Activity of faropenem against cephalosporin-resistant Enterobacteriaceae

Shazad Mushtaq
, Russell Hope
, Marina Warner
, David M Livermore

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.

Original language	English
Pages (from-to)	1025-30
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	59
Issue number	5
DOIs	https://doi.org/10.1093/jac/dkm063
Publication status	Published - May 2007

Keywords

Anti-Bacterial Agents
Cephalosporin Resistance
England
Enterobacteriaceae
Humans
Microbial Sensitivity Tests
beta-Lactams

Access to Document

10.1093/jac/dkm063

Cite this

@article{f4d494f7b6c6495a930fd82f7192a8c4,

title = "Activity of faropenem against cephalosporin-resistant Enterobacteriaceae",

abstract = "There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.",

keywords = "Anti-Bacterial Agents, Cephalosporin Resistance, England, Enterobacteriaceae, Humans, Microbial Sensitivity Tests, beta-Lactams",

author = "Shazad Mushtaq and Russell Hope and Marina Warner and Livermore, \{David M\}",

year = "2007",

month = may,

doi = "10.1093/jac/dkm063",

language = "English",

volume = "59",

pages = "1025--30",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Activity of faropenem against cephalosporin-resistant Enterobacteriaceae

AU - Mushtaq, Shazad

AU - Hope, Russell

AU - Warner, Marina

AU - Livermore, David M

PY - 2007/5

Y1 - 2007/5

N2 - There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.

AB - There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.

KW - Anti-Bacterial Agents

KW - Cephalosporin Resistance

KW - England

KW - Enterobacteriaceae

KW - Humans

KW - Microbial Sensitivity Tests

KW - beta-Lactams

U2 - 10.1093/jac/dkm063

DO - 10.1093/jac/dkm063

M3 - Article

C2 - 17353220

SN - 0305-7453

VL - 59

SP - 1025

EP - 1030

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 5

ER -